Phase 2 Metabolic Benefits Beyond weight loss, retatrutide improved cardiometabolic markers: Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose) Triglycerides: Reduced 27% from baseline Fasting glucose: Decreased 13.8 mg/dL HbA1c: Reduced 0.4% (in participants without diabetes) TRIUMPH-4: First Phase 3 Results (December 2025) TRIUMPH-4 was the first Phase 3 trial to report
If your unopened pen has been left unrefrigerated, this represents a deviation from recommended storage conditions that may compromise the medication's stability and efficacy
doi: 10.1007/s11938-020-00276-0
Walking remains one of the best exercises for digestive health
The FDA has approved Contrave for long-term weight management in adults who meet specific BMI requirements: A body mass index (BMI) of 30 kg/m or higher (obese), or A BMI of 27 kg/m or higher (overweight), plus at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol (dyslipidemia) Contrave can also be taken by: Adults looking for mild to moderate weight loss People who also have depression or binge eating disorder, Contrave may help with mood and cravings Those who prefer taking a daily pill instead of weekly injections Only approved for use in adults (18 and older) If you prefer tablets over injections or do not require significant weight loss (above 10%), Contrave may be right for you